About: The 2019–2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The 2019–2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The 2019–2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper
Creator	Izurieta, Ricardo Firstenberg, Michael Garg, Manish Paladino, Lorenzo Tucci, Veronica Di Somma, Salvatore Kelkar, Dhanashree Miller, Andrew Yaffee, Anna Chandra, Shruti El-Menyar, Ayman Galwankar, Sagar Opara, Ijeoma Papadimos, Thomas Stawicki, Stanislaw Anderson, Harry Asensio, Juan Bloem, Christina Chauhan, Vivek Cioè-Peña, Eric Dal Ponte, Silvana De Wulf, Annelies Dubhashi, Siddharth Dutta, Vibha Fatimah, Lateef Gaieski, David Garg, Sona Glaze, Krystal Grover, Joydeep Jeanmonod, Donald Jeanmonod, Rebecca Krishnan, Vimal Leyfman, Yan Munasinghe, Aruna Nanda, Sudip Saoud Al Thani, Hassan Sardesai, Indrani Sinha, Sagar Venkataramanaiah, S WB Nanayakkara, Prabath Worlton, Tamara Yellapu, Vikas
Source	Medline; PMC
abstract	What started as a cluster of patients with a mysterious respiratory illness in Wuhan, China, in December 2019, was later determined to be coronavirus disease 2019 (COVID-19). The pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel Betacoronavirus, was subsequently isolated as the causative agent. SARS-CoV-2 is transmitted by respiratory droplets and fomites and presents clinically with fever, fatigue, myalgias, conjunctivitis, anosmia, dysgeusia, sore throat, nasal congestion, cough, dyspnea, nausea, vomiting, and/or diarrhea. In most critical cases, symptoms can escalate into acute respiratory distress syndrome accompanied by a runaway inflammatory cytokine response and multiorgan failure. As of this article's publication date, COVID-19 has spread to approximately 200 countries and territories, with over 4.3 million infections and more than 290,000 deaths as it has escalated into a global pandemic. Public health concerns mount as the situation evolves with an increasing number of infection hotspots around the globe. New information about the virus is emerging just as rapidly. This has led to the prompt development of clinical patient risk stratification tools to aid in determining the need for testing, isolation, monitoring, ventilator support, and disposition. COVID-19 spread is rapid, including imported cases in travelers, cases among close contacts of known infected individuals, and community-acquired cases without a readily identifiable source of infection. Critical shortages of personal protective equipment and ventilators are compounding the stress on overburdened healthcare systems. The continued challenges of social distancing, containment, isolation, and surge capacity in already stressed hospitals, clinics, and emergency departments have led to a swell in technologically-assisted care delivery strategies, such as telemedicine and web-based triage. As the race to develop an effective vaccine intensifies, several clinical trials of antivirals and immune modulators are underway, though no reliable COVID-19-specific therapeutics (inclusive of some potentially effective single and multi-drug regimens) have been identified as of yet. With many nations and regions declaring a state of emergency, unprecedented quarantine, social distancing, and border closing efforts are underway. Implementation of social and physical isolation measures has caused sudden and profound economic hardship, with marked decreases in global trade and local small business activity alike, and full ramifications likely yet to be felt. Current state-of-science, mitigation strategies, possible therapies, ethical considerations for healthcare workers and policymakers, as well as lessons learned for this evolving global threat and the eventual return to a “new normal” are discussed in this article.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.4103/jgid.jgid_86_20
bibo:pmid	32773996
has license	cc-by-nc-sa
schema:url	https://doi.org/10.4103/jgid.jgid_86_20
resource representing a document's title	The 2019–2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper
has PubMed Central identifier	PMC7384689
has PubMed identifier	32773996
schema:publication	J Glob Infect Dis
resource representing a document's body	covid:PMC7384689#body_text
is schema:about of	named entity 'Academic Council' named entity 'Academic' named entity 'Coronavirus' named entity 'respirator' named entity 'air travel' named entity 'tort law' named entity 'flatten the curve' named entity 'invasive mechanical ventilation' named entity 'Physical distancing' named entity 'CDC' named entity 'pulmonary arterial tree' named entity 'COVID' named entity 'personal hygiene' named entity 'cardiac failure' named entity 'positive end-expiratory pressure' named entity 'respect for persons' named entity 'fatigue' named entity 'spreading the disease' named entity 'SARS-CoV-2' named entity 'social interaction' named entity 'COVID' named entity 'Singapore' named entity 'pandemics' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'national health' named entity '8.2' named entity 'executive order' named entity 'SARS-CoV-2' named entity 'sensitivity and specificity' named entity 'United States' named entity 'diabetes' named entity 'Republic of Korea' named entity 'hypertension' named entity 'ARDS' named entity 'oseltamivir' named entity 'sensitivity and specificity' named entity 'SARS-CoV-2' named entity 'multinucleated giant cells' named entity 'COVID' named entity 'PPE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software